The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys

被引:72
作者
Kadikoylu, G
Bolaman, Z
Demir, S
Balkaya, M
Akalin, N
Enli, Y
机构
[1] Adnan Menderes Univ, Fac Med, Div Hematol, Aydin, Turkey
[2] Pamukkale Univ, Fac Med, Dept Biochem, Denizli, Turkey
[3] Adnan Menderes Univ, Fac Vet Med, Aydin, Turkey
关键词
antioxidant enzymes; cisplatin; desferrioxamine; lipid peroxidation; vitamin C; vitamin E;
D O I
10.1191/0960327104ht413oa
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Cisplatin-induced nephrotoxicity is associated with an increase in lipid peroxidation and oxygen free radicals in rat kidneys. In this study, the effects of desferrioxamine were compared to vitamin C and E on cisplatin-induced lipid peroxidation and antioxidant enzyme activities in rat kidneys. Rats were divided into five groups, with 15 Wistar rats in each group. In the control group, rats received 1 mL/100 g isotonic saline solution intraperitoneally (i.p.). In Group 11, 10 mg/kg cisplatin i.p. was injected to rats. Thirty minutes before the same dosage of cisplatin administration, 100 mg/kg i.p. vitamin C or E was given to rats in groups III and IV, respectively. Rats in Group V received 250 mg/kg desferrioxamine i.p., before the same dose of cisplatin administration. All rats were killed by cervical dislocation after 72 hours. The kidneys were immediately removed and washed in cold saline. Spectrophotometric method was used for all analyses. While catalase, glutathione reductase (GR), and superoxide dismutase (SOD) levels were found to be significantly decreased (P < 0.001), malondialdehyde (MDA) (P < 0.05) and hydrogen peroxide (11202) (P < 0.001) levels were significantly increased in the cisplatin group when compared to the controls. NIDA levels were decreased by desferrioxamine (P < 0.005) as well as vitamin C and E (P < 0.05 and P < 0.001, respectively). These three compounds induced a significant increase in SOD levels (P < 0.05), but only in the vitamin C group, were SOD levels not significantly different than the levels of the controls (P > 0.05). In the desferrioxamine (P < 0.05), vitamin C and E groups (P < 0.001 for both), the cisplatin elevated H2O2 levels were decreased. None of these drugs had any effect on GR and catalase levels (P > 0.05). Desferrioxamine is useful to prevent cisplatin-induced lipid peroxidation, however, vitamin C and E are more effective on antioxidant enzymes than desferrioxamine.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 38 条
[1]   EFFECT OF DESFERRIOXAMINE ON CISPLATIN-INDUCED NEPHROTOXICITY IN NORMAL RATS [J].
ALHARBI, MM ;
OSMAN, AMM ;
ALGHARABLY, NM ;
ALBEKAIRI, AM ;
ALSHABANAH, OA ;
SABAH, DM ;
RAZA, M .
CHEMOTHERAPY, 1995, 41 (06) :448-454
[2]  
Antunes LMG, 2000, PHARMACOL RES, V41, P405, DOI 10.1006/phrs.1999.0600
[3]   CISPLATIN-INDUCED NEPHROTOXICITY AND THE MODULATING EFFECT OF GLUTATHIONE ESTER [J].
BABU, E ;
GOPALAKRISHNAN, VK ;
SRIGANTH, INP ;
GOPALAKRISHNAN, R ;
SAKTHISEKARAN, D .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1995, 144 (01) :7-11
[4]   Effect of amifostine on lipid peroxidation caused by cisplatin in rat kidney [J].
Bolaman, Z ;
Koseoglu, MH ;
Demir, S ;
Atalay, H ;
Akalin, N ;
Hatip, I ;
Aslan, D .
JOURNAL OF CHEMOTHERAPY, 2001, 13 (03) :337-339
[5]  
Bolaman Zahit, 2003, Turk J Haematol, V20, P35
[6]  
Capizzi RL, 1999, SEMIN ONCOL, V26, P72
[7]   RENAL TUBULAR FUNCTION IN PATIENTS TREATED WITH HIGH-DOSE CISPLATIN [J].
DAUGAARD, G ;
ABILDGAARD, U ;
HOLSTEINRATHLOU, NH ;
BRUUNSHUUS, I ;
BUCHER, D ;
LEYSSAC, PP .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :164-172
[8]   Cisplatin ototoxicity: Involvement of iron and enhanced formation of superoxide anion radicals [J].
Dehne, N ;
Lautermann, J ;
Petrat, F ;
Rauen, U ;
de Groot, H .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2001, 174 (01) :27-34
[9]   Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs:: Effects of antioxidant supplementation on the cisplatin nephrotoxicity [J].
Durak, I ;
Özbek, H ;
Karaayvaz, M ;
Öztürk, HS .
DRUG AND CHEMICAL TOXICOLOGY, 2002, 25 (01) :1-8
[10]  
el Daly E S, 1998, J Pharm Belg, V53, P87